Immunotherapeutic effects of pentoxifylline in type 1 diabetic mice and its role in the response of T-helper lymphocytes

Document Type : Original Article


1 Department of Microbiology, School of Veterinary Medicine, Urmia University, Urmia, Iran

2 Department of Pathobiology, School of Veterinary Medicine, Urmia University, Urmia, Iran

3 Department of Pharmacology & Toxicology, School of Veterinary Medicine, Urmia University, Urmia, Iran


Objective(s):Pentoxifylline is an immunomodulatory and anti-inflammatory agent and is used in vascular disorders. It has been shown that pentoxifylline inhibits proinflammatory [d1] cytokines production. The purpose of this study was to investigate the therapeutic effects of pentoxifylline on the treatment of autoimmune diabetes in mice.
Materials and Methods: Diabetes was induced by multiple low dose of streptozotocin (MLDS) injection (40 mg/kg/day for 5 consecutive days) in male C57BL/6 mice. After induction of diabetes, mice were treated with pentoxifylline (100 mg/kg/day IP) for 21 days. Blood glucose levels and plasma levels of insulin were measured. Splenocytes were tested for proliferation by MTT test and cytokine production by ELISA.
Results: Pentoxifylline treatment prevented hyperglycemia and increased plasma insulin levels in the diabetic mice. Aside from reducing lymphocyte proliferation, pentoxifylline significantly inhibited the production of proinflammatory interleukin 17 (IL-17) as well as interferon gamma (IFN-γ), while increased anti-inflammatory cytokine IL-10 as compared with those in MLDS group (diabetic control group).
Conclusion: These findings indicate that pentoxifylline may have therapeutic effect against the autoimmune destruction of the pancreatic beta-cells during the development of MLDS-induced type 1 diabetes in mice.


1. Atkinson MA, McLaren NK. The pathogenesis of insulin-dependent diabetes mellitus. NEngl J Med 1994; 31:1428-1436.
2. Roep BO, Peakman M. Diabetogenic T lymphocytes in human type 1 diabetes. Curr Opin Immunol 2011; 23:746-753.
3. Kolb H. Mouse models of insulin dependent diabetes: low-dose streptozotocin induced diabetes and non-obese diabetic (NOD) mice. Diabetes Metab Rev 1987; 3:751-778.
4. Hill N, Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 2002; 14:791–797.
5. Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S, Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthasedependent toxicity in mouse beta cells. Cell Mol Life Sci 2005; 62:2658–2668.
6. Rabinovitch A, Suarez-Pinzon WL. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochem Biophys 2007; 48:159–163.
7. Bacher A, Eggensperger E, Koppensteiner R, Mayer N, Klimscha W. Pentoxifylline attenuates the increase in whole blood viscosity after transfusion. Acta Anaesthesiol Scand 2005; 49:41-46.
8. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004; 25:430–436.
9. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002; 300:559–566.
10. Marcinkiewicz J, Grabowska A, Lauterbach R, Bobek M. Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. Immunopharmacology 2000; 49:335–343.
11. Takehana H, Inomata T, Niwano H, Nishii M, Matsuda C, Kohno K, et al. Immunomodulatory effect of pentoxifylline in suppressing experimental auto-immune myocarditis. Circ J 2002; 66:499–504.
12. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993; 23:1745–1751.
13. Silva JC, Rocha MF, Lima AA, Brito GA, Menezes DB, Rao VS. Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis. Inflamm Res 2000; 49:14–19.
14. Amirshahrokhi M, Ghazi-Khansar M. Thalidomide attenuates multiple low-dose streptozotocin-induced diabetes in mice by inhibition of proinflammatory cytokines. Cytokine 2012; 60:522–527.
15. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976; 193:415–417.
16. Amirshahrokhi K, Dehpour AR, Hadjati J, Sotoudeh M, Ghazi-Khansari M. Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice. Toxicol Appl Pharmacol 2008; 232:119–124.
17. Yang Z, Chen M, Fialkow LB, Ellet JD, Wu R, Nadler JL. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas 2003; 26:e99–e104.
18. Mensah-Brown EP, Stosic Grujicic S, Maksimovic D,Jasima A, Shahin A, Lukic ML. Downregulation of apoptosis in the target tissue prevents low-dose streptozotocin-induced autoimmune diabetes. Mol Immunol 2002; 38:941-946.
19. Etuk EU. Animals models for studying diabetes mellitus. Agr Biol J N Am 2010; 1:130-134.
20. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/ immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol 1995; 22:595–599.
21. Galindo-Rodriguez G, Bustamante R, Esquivel-Nava G, Salazar-Exaire D, Vela-Ojeda J, Vadillo-Buenfil M, et al. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J Rheumatol 2003; 30:2382–2384.
22. Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996; 64:193–200.
23. Stosić-Grujicić SD, Maksimović DD, Stojković MB, Lukić ML. Pentoxifylline Prevents Autoimmune Mediated Inflammation in Low Dose Streptozotocin Induced Diabetes. Dev Immunol 2001; 8:213-221.
24. MacDonald MJ, Shahidi NT, Allen DB, Lustig RH, Mitchell TL, Cornwell ST. Pentoxifylline in the treatment of children with new-onset 1 diabetes mellitus. JAMA 1994; 271:27–28.
25. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55:1139–1149.
26. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169–175.
27. Xiang FL, Lu X, Strutt B, Hill DJ, Feng Q. NOX2 deficiency protects against streptozotocin-induced beta-cell destruction and development of diabetes in mice. Diabetes 2010; 59:2603–2611.
28. Yasuda H, Jin Z, Nakayama M, Yamada K, Kishi M, Okumachi Y, et al. NO mediated cytotoxicity contributes to multiple low-dose streptozotocininduced diabetes but not to NOD diabetes. Diabetes Res Clin Pract 2009; 83:200–207.
29. Honkanen J, Nieminen JK, Gao R, Luopajarvi K, Salo HM, Ilonen J, et al. IL-17 immunity in human type 1 diabetes. J Immunol 2010; 185:1959–1967.
30. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998; 160:3513–3521.
31. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukocyte Biol 1998; 63:101–107.
32. Trajkovic V, Badovinac V, Popadic D, Hadi O, Stojkovi MM. Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression. Immunology 1997; 92:402–406.
33. Rieneck K, Diamant M, Haahr PM, Schonharting M, Bendtzen K. In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 1995; 37:131-138.
34. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4 T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34-38.
35. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, et al. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1995; 272:1313–1320.
36. Dong RP, Umezawa Y, Ikushima H, Munakata Y,
Schlossman SF, Morimoto C. Different regulatory effects of pentoxifylline on human T cell activation pathways. J Clin Immunol 1997; 17:247–252.